USPTO 2015–2025 USPTO PatentsView US Corporation

H. LEE Moffitt Cancer Center AND Research Institute Inc.

USPTO PatentsView assignee record - 247 granted patents across 34 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

247

Total patents granted

CPC technology areas

14.4

Avg claims per patent

+42%

5-year filing velocity

The verdict

H. holds 247 US patents across 34 technology areas, rank #1,664 of 50,000 tracked assignees.

#1,664
of 50,000 US assignees by volume: Top 8%
by Innovation Score (53.9/100): 14.4
avg claims per patent: +42%
filing velocity, last 5 yrs

Portfolio overview

H. LEE Moffitt Cancer Center AND Research Institute Inc. has been granted 247 US utility patents between 2015 and 2025, placing H. LEE Moffitt Cancer Center AND Research Institute Inc. at rank #1,664 across all assignees tracked by PlainPatent. This portfolio spans 34 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.4 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, H. LEE Moffitt Cancer Center AND Research Institute Inc. is one of the more focused assignees in the PatentsView dataset. By volume, H. sits between Teradata US, Inc. (248 patents, rank #1,660) and Saint-gobain Ceramics & Plastics, Inc. (247 patents, rank #1,668) - the closest US assignees by grant volume. The composite Innovation Score of 53.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 145 grants, compared with 102 in the 2015–2019 window, a +42% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. H. LEE Moffitt Cancer Center AND Research Institute Inc.'s 14.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 34 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark H. LEE Moffitt Cancer Center AND Research Institute Inc. against peers pursuing similar technology classes.

Teradata US

248
Water Pik

248
Biogen MA

247
Cambridge Enterpr…

247
Honeywell Federal…

247
J Choo

247
NICE

247
Saint-gobain Cera…

247
H LEE Moffitt Can… ◀

247

What this shows H. holds 247 patents at rank #1,664, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near H

By rank, the assignees closest to #1,664 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in H's primary technology class.

H.'s Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

H. LEE Moffitt Cancer Center AND Research Institute Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	4.0%
2016	15	6.1%
2017	20	8.1%
2018	23	9.3%
2019	34	13.8%
2020	39	15.8%
2021	16	6.5%
2022	27	10.9%
2023	17	6.9%
2024	30	12.1%
2025	16	6.5%

Which technologies does H. LEE Moffitt Cancer Center AND Research Institute Inc. patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 145

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 100

C07K - PEPTIDES 68

C07D - HETEROCYCLIC COMPOUNDS 60

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 51

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 32

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 31

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 27

G06T - IMAGE DATA PROCESSING OR GENERATION, IN GENERAL 24

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 23

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 21

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 17

G06F - ELECTRIC DIGITAL DATA PROCESSING 12

G06V - IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING 9

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 9

Top 15 of 34 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#1,664

Across all tracked assignees

Innovation Score

53.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does H. LEE Moffitt Cancer Center AND Research Institute Inc. hold?

H. LEE Moffitt Cancer Center AND Research Institute Inc. holds 247 US granted patents filed between 2015 and 2025, spanning 34 technology areas.

What is H. LEE Moffitt Cancer Center AND Research Institute Inc.'s Innovation Score?

H. LEE Moffitt Cancer Center AND Research Institute Inc. has an Innovation Score of 53.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does H. LEE Moffitt Cancer Center AND Research Institute Inc. focus on?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 145 patents. The company has filed patents in 34 CPC subclasses total.

Is H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patent filing rate increasing or decreasing?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s recent filing velocity is +42% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patents?

H. LEE Moffitt Cancer Center AND Research Institute Inc.'s patents average 14.4 claims each. This falls within the standard range, providing solid legal coverage.

How is the H. LEE Moffitt Cancer Center AND Research Institute Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

H.'s 247 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - H. ranks #1,664 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.